(VIANEWS) – The NASDAQ opens in less than one hour and Amicus Therapeutics‘s pre-market value is already 4.72% down.
Amicus Therapeutics’s last close was $11.86, 18.6% below its 52-week high of $14.57.
The last session, NASDAQ finished with Amicus Therapeutics (FOLD) jumping 3.76% to $11.86. NASDAQ jumped 0.51% to $16,399.52, following the last session’s upward trend on what was a somewhat positive trend trading session.
About Amicus Therapeutics
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Earnings Per Share
As for profitability, Amicus Therapeutics has a trailing twelve months EPS of $-0.51.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -107.04%.
Moving Average
Amicus Therapeutics’s worth is way below its 50-day moving average of $13.18 and below its 200-day moving average of $12.38.
More news about Amicus Therapeutics (FOLD).
